Sherif Kamal Pharmaceutical services and sciences

06/11/2024

https://www.facebook.com/share/p/1XojT2fFBy/

06/11/2024

New Meta-Analysis: PD-L1’s Role in Neoadjuvant Therapy for Non-Small Cell Lung Cancer (NSCLC)

A recent study highlights that combining immune checkpoint inhibitors (ICIs) with chemotherapy as neoadjuvant treatment significantly boosts complete pathological response (pCR) and event-free survival (EFS) for NSCLC patients—regardless of PD-L1 levels!

Key Findings:

• Improved pCR & EFS in NSCLC patients with all PD-L1 expression levels.
• Overall Survival: Benefits are observed primarily in patients with PD-L1 ≥1%, though more long-term data is needed.

What’s Next? Future studies with extended follow-up are essential to better understand the long-term survival impact, particularly for PD-L1 status.

06/11/2024

Study Highlight: Should L-Thyroxin Be Reduced or Discontinued in Hypothyroidism Treatment?

A new study published in Zeitschrift für Allgemeinmedizin explores whether general practitioners in Germany are open to reducing or discontinuing L-Thyroxin doses for patients with hypothyroidism, especially in cases where it may be overprescribed. Findings revealed that most doctors prefer maintaining the current dose, often due to stability in patient response and a perceived low risk from small doses. However, the study underscores the need for regular medication reviews, as “Deprescribing” could be beneficial to avoid unnecessary treatments.

Key Takeaway: Regularly assess L-Thyroxin use in patients, especially seniors, to prevent over-treatment risks like osteoporosis and atrial fibrillation.

Aufgrund von Verordnungsdaten ist davon auszugehen, dass L‑Thyroxin häufiger verordnet wird als es medizinisch indiziert ist. Sind hausärztlich Tätige bereit, Dosisreduktionen oder Absetzversuche von L‑Thyroxin vorzunehmen? Eine kleine Studie hat diese Frage untersucht.

02/11/2024

Navigating the rapidly evolving treatment landscape of CLL can be challenging for oncology HCPs.
With new targeted and immune therapies, tools like ’ CLL Interactive Treatment Decision Support Tool provide expert case-specific guidance.

See how recommendations from CLL experts can impact treatment choices and potentially improve patient care. Check it out and share your experience: clinicaloptions.com/CLLtool

”

https://clinicaloptions.com/activities/oncology/cll-tool/20157-38917/content

As a nationally recognized provider of continuing education for healthcare professionals, CCO develops, delivers, and evaluates a broad range of accredited, cutting-edge CME and CE opportunities.

02/11/2024

Did you know? If a patient with Epstein-Barr virus (EBV) is treated with amoxicillin, they’re at high risk for developing a widespread rash.

But it’s not an allergy!

This immune-mediated reaction can occur in up to 90% of EBV cases with amoxicillin and isn’t a reason to avoid penicillin in the future. Always consider EBV in unexplained rashes!

”

02/11/2024

معلومة هامة في رعاية مرضى السرطان للأطفال

صبي يبلغ من العمر 10 سنوات يخضع لبروتوكول برلين-فرانكفورت-مونستر لعلاج سرطان الدم الليمفاوي الحاد تم تشخيصه بمرض الانسداد الوريدي الكبدي (VOD)، وهي مضاعفة خطيرة تظهر من خلال آلام في البطن وتضخم الكبد والاستسقاء، وتتطلب اهتمامًا فوريًا. ما هو العلاج الأنسب؟ ديفيبروتيد - علاج معتمد من إدارة الغذاء والدواء أثبت فعاليته في تقليل معدل الوفيات في حالات VOD الشديدة مع الحفاظ على السلامة.

🔍 نقاط مهمة:

• التشخيص المبكر والعلاج السريع بديفيبروتيد يمكن أن ينقذ الحياة.
• الرعاية الداعمة مثل إدارة السوائل ومراقبة وظائف الأعضاء ضرورية.
• سرعة التصرف = تحسين النتائج.

نشر الوعي يمكن أن يحدث فرقًا! #ديفيبروتيد

02/11/2024

Critical Insight for Pediatric Cancer Care

A 10-year-old boy undergoing the BFM protocol for acute lymphoblastic leukemia developed hepatic veno-occlusive disease (VOD). This serious complication, marked by abdominal pain, hepatomegaly, and ascites, requires immediate attention. The best course of action? Defibrotide—an FDA-approved treatment that has shown to reduce mortality in severe VOD cases while maintaining safety.

🔍 Key Takeaways:

• Early diagnosis and prompt treatment with defibrotide can be lifesaving.
• Supportive care, including fluid management and organ function monitoring, is essential.
• Fast action = better outcomes.

Raising awareness can make a difference!

02/11/2024

Did you know that adhering to FDA-regulated expiration dates on eye drop bottles could significantly cut waste?

A recent study presented at by Dr. Gareth Lema and colleagues shows that ophthalmic clinics are discarding 71.9% of eye drop medication prematurely, leading to substantial cost and plastic waste. By following manufacturer expiration dates, clinics could save thousands of dollars and prevent environmental waste. One exam lane alone could save $1,328 and 207g of plastic annually! If this change was applied system-wide, the impact would be tremendous. 💡

Let’s make small changes for a big difference in sustainability and healthcare efficiency!

01/11/2024

https://www.facebook.com/share/p/14HzfUZZHC/

30/10/2024

https://www.facebook.com/share/v/eySkKXK1dQsdyHT6/

30/10/2024

https://fb.watch/vybU6Wvudr/